Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.

Clin Pharmacol Ther · 2014 · PMC4165641 · PMID 24637941

Europe PMC DOI

hedged sentences

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

marginally significantp=0.053so close (0.05 < p ≤ 0.1)

After dose escalation, group A (400mg TID) had marginally significant further increase in 12-hour mean DBP (p=0.053) but group B (600mg BID) did not achieve statistically significant increases (p=0.25).

also in 26,082 other papers

marginally statistically significantp = 0.053so close (0.05 < p ≤ 0.1)

Paired t-tests for the change in DBP between the end of the first week (Day 7, 8) at 400 mg twice daily and the DBP at the end of the week of escalated dose (Day 21, 22) demonstrated marginally statistically significant increase for Arm A 3.0 mmHg (p = 0.053, 95% CI −0.04, 6.14) and no statistically significant increase for Arm B, 1.5 mmHg (p = 0.25, 95% CI −1.11, 4.06).

also in 1,110 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.